[Clinical analysis of amphotericin B in the treatment of invasive fungal infections in 121 patients with hematologic diseases].
OBJECTIVE
To observe the efficacy and safety of amphotericin B for treatment of invasive fungal infections (IFI) in patients with hematologic diseases.


METHODS
121 patients were given amphotericin B 5 -50 mg/d for 5 - 101 d with a median of 19 d.


RESULTS
The clinical efficacy rate was 67.3%, and fungal elimination rate 66.7%. The adverse events included rigor and fever, hypokalaemia, hepatic damage, nephrotoxicity, nausea and vomiting, phlebitis and teeter.


CONCLUSIONS
Amphotericin B is still a high-efficiency drug in the treatment of IFI, although it has many side effects. With monitoring of hepatic and renal function, it is still a relatively safe and effective drug.
Jia
Lin
L
Department of Hematology, Tongji Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.
Huang
Mei
M
Liu
Wen-Li
WL
Zhang
Yi-Cheng
YC
Sun
Han-Ying
HY
Zhang
Dong-Hua
DH
Deng
Jin-Niu
JN
Zhou
Jian-Feng
JF
D000293:Adolescent; D000328:Adult; D000368:Aged; D000666:Amphotericin B / Q000627:therapeutic use*; D000935:Antifungal Agents / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009181:Mycoses / Q000188:drug therapy*; D016896:Treatment Outcome; D055815:Young Adult
D000935:Antifungal Agents; D000666:Amphotericin B